Lead Product(s) : fH1,DSP-0546LP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institutes of Biomedical Innovation, Health and nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo and Japan National Institute's universal influenza vaccine enters clinical trials
Details : fH1/DSP-0546LP is a vaccine candidate, specifically activates TLR7, being investigated for influenza.
Product Name : fH1
Product Type : Vaccine
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : fH1,DSP-0546LP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institutes of Biomedical Innovation, Health and nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daiichi Sankyo Announces Development Progress of mRNA COVID19 Vaccine in Japan
Details : DS-5670, an mRNA vaccine, being evaluated against the novel coronavirus infectious disease (COVID-19). DS-5670 induced a neutralizing activity against previously designated Variant of Concerns, including the Delta variant.
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensitrelvir Fumaric Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
Details : S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease, an orally administered antiviral drug for COVID-19, caused by the novel coronavirus (SARS-CoV-2).
Product Name : Xocova
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : Ensitrelvir Fumaric Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daiichi Sankyo Initiates Phase 1 Trial for Nafamostat Inhalation Formulation (DS-2319) in Japan
Details : DS-2319 contains nafamostat mesilate that has been formulated in an inhalation dosage form. It is being studied for treating COVID-19 since it has been shown to block membrane fusion between the viral envelope that causes COVID-19 and the host plasma cel...
Product Name : DS-2319
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KD-414
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate
Details : The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune r...
Product Name : KD-414
Product Type : Vaccine
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : KD-414
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable